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GASTROENTEROLOGY 1990:99:1414-1420 
Pancreatic Secretory Trypsin Inhibitor 
Stimulates the Growth of Rat Pancreatic 
Carcinoma Cells 
THOMAS C. FREEMAN, BRENDA J. CURRY, JOHN CALAM, 
and JAMES R. WOODBURN 
Gastroenterology Unit, Department of Medicine, Royal Postgraduate School of Medicine, 
Hammersmith Hospital, London, England; Bioscience 1, ICI Pharmaceuticals, Mereside, 
Alderley Park, Macclesfield, Cheshire, England 
Pancreatic secretory trypsin inhibitor was examined 
for growth-promoting activity on five cell lines using 
standard cell culture techniques. One cell line, AR4- 
2J, derived from a rat pancreatic acinar cell carci- 
noma, responded with significantly increased incor- 
poration of [3H]thymidine and colony formation. 
Pancreatic secretory trypsin inhibitor stimulated the 
incorporation of [3H]thymidine in liquid culture; the 
maximal increase was 61 f 10% above control 
(P -C 0.001) and was seen at a concentration of lo-’ 
mol/L. Using a soft agarose clonogenic assay, pancre- 
atic secretory trypsin inhibitor also consistently stim- 
ulated (3 assays) colony formation: the peak activity 
occurred at a concentration of lo-” mol/L which 
caused a 150 * 55% (mean + SE, P < 0.05) increase 
above control. Aprotinin had no effect on the growth 
of AR4-2J cells and pancreatic secretory trypsin 
inhibitor did not bind to the epidermal growth factor 
receptor. AR4-2 J cells were shown to produce pancre- 
atic secretory trypsin inhibitor. The study raises the 
possibility that pancreatic secretory trypsin inhibitor 
provides autocrine stimulation of tumor cell growth. 
P ancreatic secretory trypsin inhibitor (PSTI) is a small protein containing 56 amino acid residues 
that was first isolated from bovine pancreas in 1948 (11 
and has since been found in every vertebrate that has 
been studied. Pancreatic secretory trypsin inhibitor is 
present in the pancreatic acinar cells and is secreted 
into pancreatic juice where it is believed to protect 
against prematurely activated proteases. 
The possibility that PST1 may be a growth factor was 
raised when it was discovered that PST1 has some 
sequence homology with epidermal growth factor 
(EGF) and that their corresponding genes share approx- 
imately 50% homology (2,3), suggesting a common 
ancestry. Pancreatic secretory trypsin inhibitor has 
already been shown to stimulate the growth of nonneo- 
plastic cells. Rat PST1 increases the growth of mouse 
3T3 fibroblasts (4) and human PST1 stimulates the 
growth of human fibroblasts (5) and endothelial cells 
(6). 
Pancreatic secretory trypsin inhibitor has recently 
been identified in many extrapancreatic tissues, includ- 
ing the epithelia of the stomach, colon, and small 
intestine as well as in the liver, lung, kidney, and 
ovary (7-10). In addition, PST1 has been found to be 
present in tumors of the ovary (11,X?), uterus (121, and 
lung (13) and cell lines derived from tumors of the 
liver (14) and pancreas (15). Moreover, PST1 has been 
shown to bind specifically to a number of cell lines 
including two derived from colon and epidermoid 
tumors (16). These findings raised the possibility that 
PST1 plays a role in stimulating the growth of tumor 
cells. 
Therefore, the effect of PST1 on the growth of four 
tumor cell lines was examined: three, derived from 
gastric, pancreatic, and colonic tumors, were chosen 
because PST1 is normally present in these tissues (17). 
A vulva1 epidermoid carcinoma cell line was studied 
because of the association between PST1 and gyneco- 
logical tumors. Mouse 3T3 fibroblasts were studied 
because they had been reported by others to respond 
to rat PST1 (4). This study shows, for the first time, that 
human PST1 stimulates thymidine uptake and colony 
formation in the rat pancreatic acinar carcinoma cell 
line, AR4-2J, and that this cell line releases PSTI. 
Abbreviations used in this paper: EGF, epidermal growth 
factor; PSTI, pancreatic secretory trypsin inhibitor. 
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Materials and Methods 
All reagents for cell culture were obtained from 
Gibco (Paisley, Renfrewshire, Scotland] and chemicals were 
obtained from BDH (Poole, Dorset, England) unless other- 
wise stated. Human EGF (urogastrone) was kindly supplied 
by Dr. Harry Gregory (Bioscience 1; ICI Pharmaceuticals, 
Macclesfield, Cheshire, England). The sources of the cell 
lines were MKN45 human gastric carcinoma, D. Morris, 
Department of Surgery, Nottingham University, Nottingham- 
shire, England: MC26 mouse colon carcinoma, Dr. Giovana 
Blaconi, Instituto Marionegri, Milano, Italia; NIH 3T3 mouse 
fibroblasts, Dr. Natalie Tyke, Imperial Cancer Research 
Fund, London, England; AR4-2J rat pancreatic carcinoma, 
European Collection of Animal Cells in Culture, Porton 
Down, Wiltshire, England, and A431 human vulva1 epider- 
moid carcinoma, Dr. Michael Waterfield, Imperial Cancer 
Research Fund, London, England. 
Purification of Pancreatic Secretory Trypsin 
Inhibitor 
Purification of PST1 from human pancreatic juice 
was based on the method of Iwai et al. (18). Briefly, 
pancreatic juice not required for clinical investigation was 
collected from patients who had undergone external pancre- 
atic diversion for clinical reasons. The juice was mixed with 
an equal volume of sodium citrate, and the pH adjusted to 
2.5. Sodium chloride was then added to a final concentration 
of 1 mol/L and the mixture was maintained at 80°C for 40 
minutes, centrifuged at 3500g for 45 minutes at 4’C, and the 
supernatant concentrated on a C-18 Sep-Pak cartridge (Wa- 
ters Associates, Milford, MA) equilibrated with 0.05% vol/ 
vol trifluoroacetic acid in water. The cartridge was then 
eluted with 80% acetonitrile in 0.05% trifluoroacetic acid, 
and the eluent lyophilized. The eluent was reconstituted in 
0.05 mol/L ammonium bicarbonate, pH 8.1, applied to a 
1.5 x 100 cm Sephadex G-50 superfine column (Pharmacia, 
Uppsala, Sweden) and eluted with the same buffer. Frac- 
tions containing trypsin inhibitor activity were pooled, lyo- 
philized, and further purified by reverse-phase high- 
pressure liquid chromatography on a 10 x 100 mm Dynamax 
C-8 column (12 Km. 300 A; Rainin, Woburn, MA] eluted with 
a gradient of 16%-30% acetonitrile in 0.1% trifluoroacetic 
acid. Separation of PST1 into its various forms was achieved 
by chromatography on a Mono S column (Pharmacia) equil- 
ibrated with ammonium acetate 0.1 mol/L, pH 3.5, and 
eluted with a gradient of ammonium acetate 0.1 mol/L, pH 
3.5-4.5. Of three peaks of trypsin inhibitor activity which 
emerged, peaks I and III were single peaks when rerun on 
reversed-phase high-pressure liquid chromatography, 
whereas peak II separated into 2 peaks; II, and II,. The 
molecular mass of the four peaks, believed to differ only in 
the ratio of their asparagine/aspartic acid content (19), was 
determined by a ZAB-SE mass spectrometer (VG Instru- 
ments, Altrincham, Cheshire, England]. The molecular 
masses were I, 6242.5; II,. 6241.8; II,. 6241.6; III, 6242.5, 
compared with the predicted molecular mass for protonated 
PST1 of 6242.1. Amino acid-sequence analysis of peak I by a 
protein sequencer (Model 470; Applied Biosystems, Foster 
City, CA) showed that the N-terminal tridecapeptide se- 
quence of peak I was equal to that of human PSTI. 
Cell Culture 
The growth factor activity of PST1 was measured 
using two standard cell culture techniques, a liquid culture 
mitogenic assay, and a soft agarose clonogenic assay. Ini- 
tially, PST1 was screened for growth factor activity using a 
liquid culture mitogenic assay by growing the following five 
cell lines in the presence of PST1 at different concentrations: 
MKN45 human gastric carcinoma, MC26 mouse colon carci- 
noma, A431 human vulva1 epidermoid carcinoma, 3T3 
mouse fibroblasts, and AR4-2J rat pancreatic acinar cell 
carcinoma. Stimulation of growth was measured as an 
increase in the amount [“Hlthymidine incorporated into 
cells. Based on the results, further work on the effect of PST1 
on AR4-2J cells was performed using a soft agarose clono- 
genie assay, in which the stimulation of growth is measured 
as an increase in the number of cell colonies formed. In 
addition, both assay techniques were used to examine the 
effect of aprotinin on the growth of AR4-2J cells. Gastrin 
(Bachem, Saffron Walden, Essex, England) was used as a 
control in both the liquid mitogenic assay and the soft 
agarose assay, except for the studies of 3T3 fibroblasts where 
EGF was also used. In studies of the effect of aprotinin on 
the growth AR4-2J cells, EGF and 10% fetal calf serum were 
used as controls. 
Maintenance and Source of Cells 
Stock cultures of all cell lines were maintained at 
37°C in 95% air, 5% CO, in normal growth medium which 
was RPM1 1640 (Gibco) containing 10% fetal calf serum and 
1 mmol/L L-glutamine. They were maintained subconfluent 
by subculturing two or three times weekly using 0.05% 
trypsin (2.5% stock solution] and 0.02% ethylenediaminetet- 
raacetic acid. 
Liquid Culture Mitogenic Assay 
All cell lines were grown as a monolayer in liquid 
culture in the presence of PST1 (10~8-10-13 mol/L or lo-‘- 
lo-” mol/L). Gastrin (lo-’ mol/L) was used as a positive 
control in all assays except for those using 3T3 fibroblasts. 
where both gastrin (lo-* mol/L) and EGF (3 x lo-" mol/L] 
were used as controls. In studies of AJ4-2J cells in the 
presence of aprotinin (10. 7-10-12 mol/L], EGF (3 x lo-‘” 
mol/L) and 10% fetal calf serum were used as positive 
controls. Each test condition was repeated in six wells and 
the negative control in 12 wells. 
Cells were seeded into 96-well plates (Costar, Sloterweg. 
Badhoevedorp, Holland] typically at a concentration of 5 x 
lo4 per well in normal growth medium. Plates were then 
incubated in plastic boxes at 37°C for 72 hours in an 
atmosphere of 95% air and 5% CO,. At the end of this period 
the medium was removed and the test compounds and 1 &i 
of [3H]methyl thymidine (5 Ci/mmol/L; Amersham, Alyes- 
bury, Buckinghamshire, England] were added, both were 
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made up in 100 rL of serum-free medium. Plates were then 
incubated for a further 48 hours under the same conditions. 
The medium was removed from the wells by tipping onto 
absorbent paper and the cells trypsinized (0.1%) for 30 
minutes at 37°C. To each well, 150 rL of medium was added 
and triturated to mix. Cells were harvested using a Titertek 
530 cell harvester (Flow Laboratories, Rickmansworth, Hert- 
fordshire, England) and the filter papers were allowed to 
dry. The filter papers were placed into miniscintillation vials 
together with 2 mL of HP Ready Solve scintillation fluid 
(Beckman, High Wycombe, Buckinghamshire, England] and 
counted on an Intertechnique PG-4000 scintillation counter 
(Kontron Instruments, Watford, Hertfordshire, England). 
Soft Agarose Clonogenic Assay 
Based on the results obtained from the liquid culture 
mitogenic assay, further experiments on the growth factor 
activity of PST1 were performed using a soft agarose clono- 
genie assay. A base layer was prepared in a 35-mm plastic 
Petri dish (Costar) by pipetting 1-mL aliquots of 1% Sea 
Plaque agarose (FMC Bioproducts, Rockland, ME] in nor- 
mal growth medium. The dishes were poured and the base 
layers allowed to set for 10 minutes at 4°C. Before assay, the 
cell suspension was passed through a spinal tap needle two 
or three times so as to obtain a single cell suspension. The 
cells were then used quickly to prevent aggregation and 
dishes were seeded at two different densities to allow for 
errors in calculating cell density. Final cell count was 
typically 2 x lo4 per dish. 
The top layer of the dishes were prepared from 5 mL of 
1% agarose, 2.5 mL cell suspension, and 2.5 mL of test 
compound so as to give the required final concentration. 
Each test condition was repeated on four dishes and the 
control on 12 dishes. The assay was used to test PST1 
(10~7-10-‘2 mol/L) and aprotinin (10-7-10-12 mol/L). Gastrin 
(lo-” mol/L) was used as a positive control. Petri dishes 
were incubated for 10 days at 37°C and the colonies counted 
using a 40-10 image analyzer (AMS, Saffron Walden, Essex, 
England). 
Pancreatic Secretory Trypsin 
Inhibitor/Epidermal Growth Factor Binding 
Studies 
AR4-2J cells were maintained in normal growth 
medium before seeding out into 24 well plates (Costar] at 1 x 
lo6 per well. The plates were incubated for 2 days at 37°C 
and just before incubation with radiolabel, the cells were 
washed twice with assay buffer [Earles balanced salts 
(Sigma, Poole, Dorset, England), 50 mmol/L HEPES, 4.5 mL 
22% bovine serum albumin/L (Ortho Diagnostics, Raritan, 
NJ), 10 mL aprotinin/L, pH 7.01. Incubation was with 0.1 
nmol/L ‘?-EGF (Amersham) alone or in the presence of 
unlabeled EGF (10m6 mol/L) or PST1 (lo-“-lo-* mol/L) in 
assay buffer for 45 minutes at 25°C. At the end of the 
incubation period the cells were washed three times with 1 
mL of cold phosphate-buffered saline, lysed with 1 mL of 
NaOH (0.1 mol/L), Na,CO, (0.2 mol/L), sodium dodecyl 
sulphate (35 mmol/L), and 800 PL of the suspension counted 
on a gamma counter (LKB 1272 Clinigamma; Pharmacia, 
Milton Keynes, Buckinghamshire, England), 
Examination of AR4-21, A431, and MKN45 
Culture Media for Pancreatic Secretory 
Trypsin Inhibitor 
Culture medium in which AR4-2J cells had been 
grown and the other unused mediums (650 mL of each) were 
centrifuged at 2500g for 30 minutes at 4°C and the superna- 
tant was extracted in the same manner as human pancreatic 
juice to the point of being concentrated on a Cl8 Sep-Pak 
cartridge (Waters, Watford, Hertfordshire, England) and 
lyophilized. 
Extraction of rat PST1 was based on the method described 
by Greene et al. (19). Pancreas glands were collected from 
recently killed rats, rapidly frozen on solid carbon dioxide, 
and stored at -20°C until extraction. The pancreas glands 
were then suspended in 5 volumes (wt/vol] of 0.1 mmol/L 
diisopropyl phosphofluoridate at 4°C and homogenized in a 
blender for 2 minutes. The suspension was adjusted to pH 
4.5 with 6 mol/L HClO, and centrifuged at 2500 g for 45 
minutes at 4°C. The sediment was then reextracted and the 
combined supernatants brought to 70% saturation by the 
slow addition of 472 g/L of ammonium sulphate at 4°C. 
After centrifugation at 2500 g, 4°C for 45 minutes, the 
supernatant was discarded. The precipitate was resus- 
pended in 0.1 mmol/L diisopropyl phosphofluoridate and 
stored at -20°C. The extract was then applied to a column 
(5 x 100 cm) packed with Sephadex G-75 (Pharmacia) previ- 
ously equilibrated with 0.5 mol/L KCl, 0.1 mol/L ammonium 
acetate buffer, pH 4.5. Fractions containing trypsin-inhibitor 
activity were pooled, lyophilized, and stored at -20°C. The 
inhibitor was further purified on a G-50 column (1.5 x 100 
cm] in 0.05 mol/L ammonium bicarbonate pH 8.1. Fractions 
containing trypsin-inhibitor activity were pooled and lyo- 
philized. 
The Sep-Pak cartridge eluent obtained by extracting the 
unused and AR4-2J cell culture medium and a small portion 
of the rat PST1 were reconstituted in 1 mL of 0.1% trifluoro- 
acetic acid, applied to a 10 x 100 mm Dynamax C-8 column 
(12 Wm. 300 A, Rainin), and eluted with 16%-30% acetoni- 
trile in 0.1% trifluoroacetic acid with isocratic elution at 20% 
acetonitrile. The fractions were lyophilized and tested for 
trypsin-inhibitor activity using N-a-benzoyl-DL-arginine p-ni- 
troanilide as a substrate (20). 
Growth medium (50 mL) in which A431 and MKN45 cells 
had been grown, was treated in a similar manner to that 
described above for the AR4-2J growth medium. However, 
the Sep-Pak cartridge eluates were reconstituted in 0.5 mL 
H,O and 50 PL was tested in duplicate for PST1 using a 
specific radioimmunoassay for human PST1 developed at 
the Hammersmith Hospital (17). 
Results 
The initial screen of the five test-cell lines using 
the liquid culture mitogenic assay showed PST1 to 
stimulate the incorporation of [3H]thymidine into 
AR4-2J cells. In one assay (two plates/fraction) exam- 
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ining the effects of the different chromatographic 
forms of PST1 on thymidine incorporation into AR4-2J 
cells, PST1 peak I had more growth-factor activity 
than the other three peaks (Figure 1). Pancreatic 
secretory trypsin inhibitor peak I had most effect at a 
concentration of lo-’ mol/L. This produced an in- 
crease in the uptake of thymidine by 61 + 10% 
(P < 0.001). This effect was similar to the effect of the 
positive control which was gastrin at lo-’ mol/L 
[Figure 1). The other four cell lines, MKN 45, MC26, 
A431, and 3T3, showed no response to PST1 (Figure 2). 
Mouse 3T3 fibroblasts did not respond to either gastrin 
or PST1 in the liquid culture mitogenic assay but 
showed 147%-193% increases in thymidine uptake 
above control in the presence of EGF (3 x lo-” 
mol/L). 
Soft agarose clonogenic assay showed PST1 peak III 
to stimulate colony formation consistently in the rat 
pancreatic acinar cell line, AR4-2J, in 3 assays. Peak 
activity occurred at lo-” mol/L, (Figure 3) causing a 
150 + 55% (mean t SE, P < 0.05) increase in colony 
formation above control. In this assay, PST1 had 
slightly more activity than the positive control, gastrin 
(lo-” mol/L). Aprotinin also had no effect on either 
thymidine incorporation or colony formation by AR4-2J 
cells when it was added into the culture medium at a 
concentration range of 10-7-10-12 mol/L (Figure 4). 
When AR4-2J cells were incubated with lz51-EGF, 
94% of bound tracer could be displaced in the pres- 
ence of an excess of cold EGF. In the presence of 
unlabeled PST1 (10-8-10-” mol/L) no detectable 
,~‘_,~‘_,,‘_,o’_g ‘.8 
C 10 10 IO 10 10 IO G-17 
PST1 CONCENTRATION (M) 
Figure 1. Stimulation of [3H]thymidine incorporation into the rat 
pancreatic carcinoma cell line, AI&2J, by forms I, II,, II,. and III of 
human PSTI in liquid culture mitogenic assay. Positive control is 
gastrin-17 (10-O mol/L) The vertical axis indicates the change in 
[3Hjthymidine uptake. ‘P < 0.05, **P < 0.005, ***P < 0.001 
compared with control. 
C ,0”~,0-‘~,6”,o-‘~,o~~,O=G-l 7 c 10 
-12 -II .I0 4 ,o.¶ ,o-7G_, , 
10 10 10 
PST1 CONCENTRATION (M) 
Figure 2. Investigation of possible stimulation of [‘Hlthymidine 
incorporation into (A) human vulval epidermoid carcinoma cell 
line, A431, [B) human gastric carcinoma cell line, MKN45, (C) 
mouse colon carcinoma cell line, MC26, and (D) 3T3 mouse 
ilbroblasts in the presence of PSTI in a liquid culture mitogenic 
assay. Gastrin-17 (lo-” mol/L] was used as a control in each study 
and in (D) EGF (3 x 10-l’ mol/L) was also used as a control. The 
vertical axis indicates the change in [Hlthymidine uptake. ***PC 
0.001 compared with control. 
inhibition of the binding of the lz51-EGF was observed 
(Figure 5). 
Analysis of the culture medium extracts on reverse- 
phase, high-pressure liquid chromatography showed a 
peak of trypsin-inhibitor activity that was present in 
the medium conditioned by AR4-2J cells but not in the 
unused medium extract. The peak of trypsin-inhibitor 
activity eluted in about the same position as rat 
pancreatic PST1 (Figure 6). Analysis of the culture 
medium in which A431 and MKN45 cells had been 
6 250 
E 
s -50 ! 
ii C -12 10 10 -11 10 -10 11 IO” Id G-17 
PST1 CONCENTRATION (M) 
Figure 3. Stimulation of colony formation of the rat pancreatic 
carcinoma cell line, AB4-2 J, by PSTI (peak III) in soft agarose assay. 
Positive control was gastrhr-17 (10-l’ mol/L). *P < 0.05 compared 
with control. 
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APROTININ CONCENTRATION (M) 
Figure 4. The effect on 13H]thymidine incorporation in the rat 
pancreatic carcinoma cell line, AR4-2J, grown in the presence of 
aprotinin in liquid culture mitogenic assay. Positive controls were 
EGF (3 x 10 lo mol/L) and 10% fetal calf serum. **P -C 0.01, ***P < 
0.001 compared with the control. 
grown showed the extract to contain no detectable 
PSTI-like immunoreactivity (~20 rig/L of medium]. 
Discussion 
In this study we have shown that human PST1 
stimulates the growth of AR4-2J cells which are de- 
rived from a rat pancreatic acinar carcinoma cell line. 
We have also demonstrated that these cells release 
PSTI. These two findings raise the possibility that 
PST1 may be an autocrine stimulant of tumor-cell 
growth. 
This study is the first to show that PST1 can stimu- 
late the growth of neoplastic cells. Earlier studies have 
shown that one of the two forms of rat PSTI, monitor 
peptide, stimulates thymidine and methionine incorpo- 
ration as well as increases the cell number of 3T3 
mouse fibroblasts in liquid culture (4). However, we 
were unable to demonstrate an effect of human PST1 
on the incorporation of thymidine into these cells 
i., 
.a._ 
‘..* 
‘._ 
i 
l. 
\ 
0, . , , . , , . , 
10 
.11 10 
-10 10.9 10.6 lo-? 
CONC. COLD PEPTIDE (M) _._._.__._._ EG F 
- PST1 
Figure 5. The binding of ‘9-EGF (percent specific binding) to 
AR4-2J rat pancreatic carcinoma cells in the presence of different 
concentrations of PSTI. 
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Figure 6. The elution profile of trypsin-inhibitor activity extracted 
from (A) rat pancreas and (B) growth medium in which AR4-2J 
cells had been grown from reverse-phase, high-pressure liquid 
chromatography (Dynamax, G-6, 10 x 100 mm, 12 pm, 300 A). 
(H) Trypsin-inhibitor units/fraction, (-1% acetonitrile. 
under the conditions that we used. Human PST1 has 
been shown to stimulate the uptake of thymidine into 
human fibroblasts (5) and to stimulate the growth of 
human endothelial cells (6). 
There are similarities between PST1 and EGF and, 
at present, there is controversy as to whether PST1 
stimulates growth by interacting with EGF receptors 
or other receptors. The human peptides are of a 
similar size, PST1 containing 56 amino acid residues 
and EGF containing 53: both have three disulfide 
bridges (21). Analysis of their respective genes shows 
about 50% homology, suggesting a common ancestral 
origin (2). Also, the results of binding studies suggest 
that rat PST1 competes with EGF for binding to 
receptors on 3T3 mouse fibroblasts (22). However, only 
7 of the 56 amino acid residues comprising human 
PST1 are homologous with those of human EGF (3). 
Niinobu et al. (16) examined the binding of PST1 to 
nine cell lines and found human PST1 to bind to eight 
of the cell lines including five fibroblast lines, an 
endothelial cell line, and two tumor cell lines derived 
from an epidermoid and colon carcinoma. However, 
the binding of PST1 to the cell lines did not correlate 
with the binding of EGF to the same cell lines, 
suggesting in this case that PST1 was binding to a 
November 1996 PST1 AND PANCREATIC CANCER CELL GROWTH 1419 
different receptor. Our results support this view. Out 
of the five cell lines tested in this study, 3T3, MKN45, 
and AR4-2J were EGF responsive in our hands but 
only one of these, the AR4-2J cell line, was stimulated 
by PSTI. This was demonstrated in the liquid culture 
mitogenic assay of mouse 3T3 fibroblasts which re- 
sponded well to EGF but not to PSTI. In addition, our 
studies demonstrated that the binding of lz51-EGF to 
AR4-2J cells was unaffected in a loo-fold excess of 
cold PSTI. It now seems important to characterize the 
PST1 binding site that is present on normal and 
neoplastic cells (16). In view of the differences in the 
growth-stimulating effects of the different forms of 
human PST1 shown in this study, it seems likely that 
deamidation of PST1 affects its binding to such sites. 
McKeehan et al. found that the growth of human 
endothelial cells was stimulated by the trypsin inhibi- 
tors aprotinin and ol,-antitrypsin as well as PST1 (6). 
This could reflect the similarities between inhibitor/ 
enzymes and growth-factor/receptor interactions, per- 
haps reflecting an ancient common origin. Alterna- 
tively, the trypsin inhibitors could protect other growth 
factors from extracellular proteases as cultured endo- 
thelial cells exhibit significant proteolytic activity. 
However, unlike PSTI, aprotinin did not stimulate the 
growth of AR4-2 J cells. 
AR4-2J cells secrete amylase and trypsinogen, and 
in the normal pancreas these are cosecreted with 
PSTI. Therefore, our chromatographic demonstration 
that AR4-2J cells produce PST1 confirmed what was 
expected but had not been demonstrated previously. It 
is of particular interest that the human pancreatic 
cancer cell line CAPAN- also produces large amounts 
of PST1 (15) and that three other human pancreatic 
cell lines show PST1 immunoreactivity (23). Rat PST1 
has been fully characterized by others and found to 
comprise two discrete forms. Rat PSTI-I contains 61 
amino acid residues and possesses cholecystokinin- 
releasing activity and has been called monitor pep- 
tide. Rat PSTI-II has 71% homology with rat PSTI-I 
and 63% homology with human PST1 and, like human 
PSTI, contains 56 amino acid residues (24). 
Malignant tumors of a variety of organs are often 
accompanied by increased serum and urine concentra- 
tions of PST1 (8,23,25,26] which, before being identi- 
fied as PST1 (271, was known as tumor-associated 
trypsin inhibitor. Extrapancreatic human tumors also 
produce PSTI. A hepatoblastoma cell line (14) se- 
creted PSTI, and PST1 was found to be present in cell 
lines derived from gastric cervical cancers (23) and a 
hepatoma (6). Pancreatic secretory trypsin inhibitor 
has been identified in ovarian (ll,12) and cervical 
cancers (12) and messenger RNA encoding PST1 was 
present in a pulmonary adenocarcinoma and in a 
colonic polyp (13). 
The stimulation of the growth of AR4-2J cells by 
PST1 which is itself secreted by these cells, raises the 
important possibility that PST1 acts as an autocrine 
stimulant of neoplastic growth. Further studies will 
examine the effect of specific immunoneutralization 
of PST1 on tumor-cell growth. The findings of others 
suggest that such studies should be extended to tumors 
other than those of the pancreas. 
I. 
2. 
3. 
4. 
5. 
6. 
7. 
a. 
9. 
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11. 
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